Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report

Neurol Sci. 2021 Mar;42(3):1175-1177. doi: 10.1007/s10072-020-04728-4. Epub 2020 Sep 24.

Authors

Seyed Mohammad Baghbanian¹, Mohammad Reza Mahdavi Amiri²

Affiliations

¹ Neurology Department, Booalisina Hospital, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. sm.baghbanian@mazums.ac.ir.
² Medical Genetics, School of Allied Medical Sciences, Thalassemia Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.

PMID: 32968870
DOI: 10.1007/s10072-020-04728-4

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Fingolimod Hydrochloride / adverse effects
Humans
Immunosuppressive Agents / adverse effects
Meningoencephalitis* / chemically induced
Meningoencephalitis* / diagnosis
Meningoencephalitis* / drug therapy
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride